Evidence map›Paper›PMID 36139666›Full record

ArticleCancers2022

The Effect of

Connor E Stewart, María E Guerra-García, Lixia Luo, Nerissa T Williams, Yan Ma, Joshua A Regal, Debosir Ghosh, Patrick Sansone, Mark Oldham, Katherine Deland and 3 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Connor E StewartDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
María E Guerra-GarcíaDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Lixia LuoDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Nerissa T WilliamsDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Yan MaDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Joshua A RegalDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-5142-0978
Debosir GhoshDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Patrick SansoneDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0001-8060-6026
Mark OldhamDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Katherine DelandDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Oren J BecherDepartment of Pediatrics, Mt. Sinai Hospital, New York, NY 10029, USA.ORCID 0000-0003-4016-8492
David G KirschDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.
Zachary J ReitmanDepartment of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA.ORCID 0000-0002-9122-9550
Duke Medical Center · USSinai Hospital · US

Funding

Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI JOHN N. NORTON · 1985 to 2026
$174.8M
Targeted Alpha-Particle Radiotheraphy of Brain Tumors with 211At-81C6 AntibodyP50CA190991 · NCI · DUKE UNIVERSITY · PI SAMPSON, JOHN H. · 2014 to 2023
$20.8M
Advancing Cancer Therapy through Ground Breaking Research in Radiation BiologyR35CA197616 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI David Guy Kirsch · 2016 to 2026
$10.7M
Biomarker, Bioinformatics and Biorepository CoreU19CA264385 · NCI · DUKE UNIVERSITY · PI Mustafa Khasraw, Jerry William Shay · 2021 to 2026
$5.4M
Enhancing the efficacy of Radiation Therapy for brainstem glioma by targeting ATMK08CA256045 · NCI · DUKE UNIVERSITY · PI Zachary Reitman · 2022 to 2026
$1.1M
Image-Guided Radiation Therapy System for Small AnimalsS10OD028575 · OD · DUKE UNIVERSITY · PI PALMER, GREGORY MATHEW · 2021 to 2021
$600k
NCI NIH HHS K08 CA256045NCI NIH HHS K08CA256045, U19CA264385, P50CA190991, R35CA197616, P30CA014236NCI NIH HHS P30 CA014236NCI NIH HHS P50 CA190991NCI NIH HHS R35 CA197616NCI NIH HHS U19 CA264385NIH HHS S10 OD028575
6 · The paper itself

Abstract

Diffuse midline gliomas arise in the brainstem and other midline brain structures and cause a large proportion of childhood brain tumor deaths. Radiation therapy is the most effective treatment option, but these tumors ultimately progress. Inhibition of the phosphoinositide-3-kinase (PI3K)-like kinase, ataxia-telangiectasia mutated (ATM), which orchestrates the cellular response to radiation-induced DNA damage, may enhance the efficacy of radiation therapy. Diffuse midline gliomas in the brainstem contain loss-of-function mutations in the tumor suppressor

Indexed as

ATMdiffuse midline gliomaDIPGgenetically engineered mouse modelsradiation therapy

Identifiers

PMID36139666
PMCPMC9496888
OpenAlexW4296312428

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.